Alcon EBITDA 2019-2022 | ALC
Alcon annual and quarterly EBITDA history from 2019 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Alcon EBITDA for the quarter ending September 30, 2022 was $0.469B, a 3.53% increase year-over-year.
- Alcon EBITDA for the twelve months ending September 30, 2022 was $1.942B, a 1.2% increase year-over-year.
- Alcon 2021 annual EBITDA was $1.8B, a 57.34% increase from 2020.
- Alcon 2020 annual EBITDA was $1.144B, a 9.85% decline from 2019.
- Alcon 2019 annual EBITDA was $1.269B, a 7.64% decline from 2018.
Alcon Annual EBITDA
(Millions of US $) |
| 2021 |
$1,800 |
| 2020 |
$1,144 |
| 2019 |
$1,269 |
| 2018 |
$1,374 |
Alcon Quarterly EBITDA
(Millions of US $) |
| 2022-09-30 |
$469 |
| 2022-06-30 |
$525 |
| 2022-03-31 |
$509 |
| 2021-12-31 |
$439 |
| 2021-09-30 |
$453 |
| 2021-06-30 |
$475 |
| 2021-03-31 |
$433 |
| 2020-12-31 |
$558 |
| 2020-09-30 |
$301 |
| 2020-06-30 |
$-67 |
| 2020-03-31 |
$352 |
| 2019-12-31 |
$310 |
| 2019-09-30 |
$351 |
| 2019-06-30 |
$308 |
| 2019-03-31 |
$300 |
| 2018-12-31 |
|
| 2018-09-30 |
$388 |
| 2018-06-30 |
$38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$37.369B |
$8.291B |
|
Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
|
